17 August 2020: Animal Study
Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling
Dong-shan Zhu 1ABCDEF , Jing-yao Dong 1BCF , Yao-yao Xu 2BCD , Xin-tong Zhang 2BCD , Shi-bo Fu 2ACEFG* , Wei Liu 1ACEFG*DOI: 10.12659/MSM.927106
Med Sci Monit 2020; 26:e927106
Table 1 EC50 of 5 compounds for growth inhibition in Esophageal squamous cell carcinoma (ESCC) cell lines.
| Compound | Target | EC50 for 4 OSCC cells (nM, SD) | |||
|---|---|---|---|---|---|
| KYSE70 | KYSE150 | KYSE180 | KYSE520 | ||
| Carfilzomib | Proteasome | 22.78±7.99 | 8.20±1.26 | 15.74±1.32 | 14.61±4.60 |
| Delanzomib | Proteasome | 32.85±3.44 | 12.90±1.43 | 33.53±5.58 | 44.22±14.24 |
| Ixazomib | 20S proteasome | 253.97±132.90 | 355.09±195.70 | 237.03±92.29 | 163.21±67.37 |
| Digoxin | Na, K-ATPase | 121.98±24.37 | 294.85±43.17 | 304.27±36.29 | 185.17±36.09 |
| Omipalisib | PI3K/mTOR | 138.87±10.18 | 163.80±21.34 | 160.17±30.14 | 122.59±26.03 |
| EC – concentration for 50% of maximal effect; SD – standard deviation. | |||||